Drug Trial Radar · NCT06284122
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
790
Planned (sponsor's estimate)
Start
Jun 7, 2024
Primary completion
Nov 2028
Study completion Apr 2034
Sponsor
- Lead sponsor
- The Lymphoma Academic Research OrganisationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Lymphoma Study Association; Swiss Cancer Institute; Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal antibody (mAb) plus chemotherapy in patients with previously untreated FLIPI 2-5 follicular lymphoma.
Conditions
- Follicular Lymphoma
Interventions
MosunetuzumabDrug
5 mg (step-up dosing) Day 1 of C1 45 mg Day 8 and Day 15 of C1, 45 mg Day 1 from C2 to C12, 45 mg Day 1 from C13 to C21
LenalidomideDrug
Lenalidomide starting dose is based on patient's creatinine clearance. Day 1 to Day 21 from C2 to C12
RituximabDrug
when associated to CHOP IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C20
ObinutuzumabDrug
when associated to CHOP 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C18
CyclophosphamideDrug
750 mg/m2 Day 1 from C1 to C6
DoxorubicinDrug
50 mg/m2 Day 1 from C1 to C6
VincristinDrug
1.4 mg/m2 (cap cf. below)$ Day 1 from C1 to C6
PrednisoneDrug
100 mg/day Day 1 to Day 5 from C1 to C6
RituximabDrug
when associated to bendamustin IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C18
ObinutuzumabDrug
when associated to bendamustin 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C20
BendamustinDrug
90 mg/m2 Day 1 and Day 2 from C1 to C6
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: 130 PFS events assessed by an Independent Review Committee (IRC) (4.6 years)
- Progression Free Survival (PFS)Time frame: 173 PFS events assessed by IRC (5.8 y)
Locations
111 sites in 7 countries. Site status is shown where the registry gives one.
Krankenhaus der Barmherzigen Brüder Graz - Abteilung Für Innere Medizin I
Graz, Austria
Krems University Hospital - Abteilung Für Innere Medizin 2
Krems, Austria
LKH HOCHSTEIERMARK - Department für Hämato-Onkologie
Leoben, Austria
Kepler Universitaetsklinikum - Univ.-Klinik für Hämatologie und Internistische Onkologie
Linz, Austria
Paracelsus Medical University - 3rd Medical Department
Salzburg, Austria
Univ. Klinikum ST.PÖLTEN - Klinische Abteilung Für Innere Medizin 1
Sankt Pölten, Austria
Medical University of Vienna - Department of Hematology and Hemostaseology
Vienna, Austria
Klinikum Wels-Grieskirchen GMBH - IVth Internal Department
Wels, Austria
AZ SINT-JAN BRUGGE - OOSTENDE AV - Service Hématologie
Bruges, Belgium
INSTITUT JULES BORDET - Service Hématologie
Brussels, Belgium
UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Service Hématologie
Brussels, Belgium
GRAND HOPITAL DE CHARLEROI - Service Hématologie
Charleroi, Belgium
UNIVERSITAIR ZIEKENHUIS GENT - Service Hématologie
Ghent, Belgium
HELORA - Hôpital de La Louvière - Site Jolimont - Service Hématologie Clinique
La Louvière, Belgium
CHU DE LIEGE - Service Hématologie
Liège, Belgium
CHU UCL NAMUR - SITE GODINNE - Service Hématologie
Yvoir, Belgium
CH d'AVIGNON - HOPITAL HENRI DUFFAUT - Service d'Onco-Hématologie
Avignon, France
CH DE LA COTE BASQUE - Service Hématologie
Bayonne, France
CHU JEAN MINJOZ - Service Hématologie
Besançon, France
INSTITUT BERGONIE - Service d'Oncologie Médicale
Bordeaux, France
CENTRE HOSPITALIER JEAN ROUGIER - Service d'Oncologie - Hématologie
Cahors, France
CH METROPOLE SAVOIE - SITE CHAMBERY - Service Hématologie
Chambéry, France
CHU ESTAING - Service Thérapie Cellulaire et Hématologie Clinique
Clermont-Ferrand, France
HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes
Créteil, France
CHU DIJON BOURGOGNE - Service Hématologie Clinique
Dijon, France
CHD DE VENDEE - Service Hématologie
La Roche-sur-Yon, France
CHU DE GRENOBLE - Service Hématologie
La Tronche, France
HOPITAL SAINT VINCENT-DE-PAUL - Service Hématologie
Lille, France
CHRU DE LILLE - HOPITAL CLAUDE HURIEZ - Service Hématologie
Lille, France
CHU DE LIMOGES - HOPITAL DUPUYTREN - Service Hématologie Clinique et Thérapie Cellulaire
Limoges, France
INSTITUT PAOLI CALMETTES - Service Hématologie
Marseille, France
CHU DE MONTPELLIER - Département d'Hématologie Clinique
Montpellier, France
GH REGION MULHOUSE ET SUD ALSACE - HOPITAL EMILE MULLER - Service Hématologie
Mulhouse, France
CHU DE NANTES - Service Hématologie
Nantes, France
CENTRE HOSPITALIER DE NIORT - Médecine interne
Niort, France
HOPITAL SAINT-LOUIS - Service Hématologie
Paris, France
CHU DE BORDEAUX - HOPITAL HAUT-LEVEQUE - CENTRE FRANCOIS MAGENDIE - Service d'Hématologie et Thérapie Cellulaire
Pessac, France
CHU LYON-SUD - Hématologie
Pierre-Bénite, France
CHI POISSY SAINT-GERMAIN-EN-LAYE - Service Hématologie
Poissy, France
CHU DE POITIERS - HOPITAL DE LA MILETRIE - Service d'Oncologie Hématologique et Thérapie Cellulaire
Poitiers, France
Showing 40 of 111 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.